Cyclosporine A in hospitalized COVID-19 pneumonia patients to prevent the development of interstitial lung disease: a pilot randomized clinical trial
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.This pilot study found cyclosporine A (CsA) did not significantly prevent post-COVID-19 interstitial lung disease (ILD) in hospitalized patients. Further research is needed to explore CsA
Area Of Science
- Pulmonology and Infectious Diseases
- Clinical Pharmacology
Background
- Post-COVID-19 interstitial lung disease (ILD) is a significant concern, potentially leading to chronic pulmonary fibrosis.
- Understanding effective treatments for preventing ILD after severe COVID-19 pneumonia is crucial.
Purpose Of The Study
- To investigate the efficacy and safety of cyclosporine A (CsA) in preventing the development of ILD in patients hospitalized with COVID-19 pneumonia.
- To assess CsA's impact on medium-term ILD development and need for invasive mechanical ventilation (IMV).
Main Methods
- A single-center, parallel-group, open-label pilot randomized clinical trial.
- 33 hospitalized COVID-19 pneumonia patients were randomized 1:1 to receive CsA plus standard of care (n=17) or standard of care alone (n=16).
- Primary outcome: percentage of patients without ILD at 3 months post-diagnosis, not requiring IMV.
Main Results
- No significant difference was observed between groups for the primary outcome (response without requiring IMV).
- No significant difference was found for the secondary outcome of response requiring IMV.
- A trend towards improved response irrespective of IMV was noted in the CsA group (p=0.057), but not statistically significant.
- Adverse events were similar between the CsA and standard care groups.
Conclusions
- This pilot study could not demonstrate a significant effect of cyclosporine A in preventing the development of interstitial lung disease in hospitalized COVID-19 patients.
- Further investigation with larger cohorts may be warranted, but current evidence does not support CsA for this indication.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
Related Concept Videos
Transmission-based precautions are for patients infected or suspected to be infected (or colonized) with organisms posing a significant risk to others. The transmission precautions include airborne and protective environment precautions.
Airborne precautions:
Use airborne precautions when treating patients known or suspected to have diseases that spread through the air—for example, tuberculosis or measles. These organisms are present in smaller droplets expelled by an infected person and...
Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
• For...
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...